
Vaccine Stocks Tumble as Pfizer Slashes Outlook
Stocks of Pfizer, BioNTech, Moderna, and Novavax fell in premarket trading as demand for Covid vaccines plummeted, leading to a change in fortune for the sector. Pfizer slashed its revenue forecasts due to sliding demand for its Covid-19 products, including its mRNA shot and antiviral drug Paxlovid. The company also announced a $3.5 billion cost-cutting program. Moderna, which heavily relies on its Covid-19 vaccines, will report its quarterly earnings soon and is vulnerable to sliding demand.
